Shire/Baxalta Merger's Benefits Doubted By Wall Street
This article was originally published in Scrip
Executive Summary
The successful culmination of Shire PLC's months-long pursuit of Baxalta Inc. to create the world's biggest rare disease company generally was seen as a good thing by analysts, but they question how much value acquiring the Baxter International Inc. spinout for approximately $32bn truly will bring to the Irish specialty pharma. Concerns center on the long-term viability of Baxalta's hemophilia franchise and whether the total benefits warrant the price being paid.
You may also be interested in...
Shire May Split Up – But Punting On Bigger Decisions For Now
The specialty pharma is dividing its operations into rare disease and neuroscience units, but whether that will mean a spinout for the latter won't be revealed for months.
Shire Outlines Baxalta Integration Strategy
First quarter financial results brought another growth period for Shire PLC, but perhaps the most noteworthy information provided by the company on its April 29 earnings call, was its strategy for integrating Baxalta Inc. into its infrastructure, assuming both companies' boards approve the transaction when they meet separately on May 27.
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.